MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells - Wikidata - awgldk - TriplyDB

MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells

MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells

http://www.wikidata.org/entity/Q33638962

about

The detection, treatment, and biology of epithelial ovarian cancer Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling)T Lymphocyte-Endothelial Interactions: Emerging Understanding of Trafficking and Antigen-Specific Immunity Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer Ocular surface mucins and local inflammation--studies in genetically modified mouse lines Targeted immune therapy of ovarian cancer Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody Effects of the loss of conjunctival Muc16 on corneal epithelium and stroma in mice MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.Characteristics of highly polymorphic segmental copy-number variations observed in Japanese by BAC-array-CGH MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing.The immunomodulating roles of glycoproteins in epithelial ovarian cancer.Differential expression of proteins in naïve and IL-2 stimulated primary human NK cells identified by global proteomic analysis.Immunity and immune suppression in human ovarian cancer.Transmembrane mucins as novel therapeutic targets B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape.Antigen recognition is facilitated by invadosome-like protrusions formed by memory/effector T cells.The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia.Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.Manifestations of immune tolerance in the human female reproductive tract.MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism.Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB.A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis.Therapeutic targets and new directions for antibodies developed for ovarian cancer.Novel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients.Tumour immunomodulation: mucins in resistance to initiation and maturation of immune response against tumours.Human NK cells: from surface receptors to the therapy of leukemias and solid tumors Effect of tumor cells and tumor microenvironment on NK-cell function.Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.Role of NK cells in immunotherapy and virotherapy of solid tumors.IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.Viewing Siglecs through the lens of tumor immunology.

P2860

Q21198791-D9A5E9C1-09EE-4162-82F2-E34756C1F5C1 Q24601584-3C8ABA4A-391B-4A2E-883E-5D327D5132C0 Q26739942-9AE0E2A6-9841-4F48-BBFD-D00001F36DE8 Q26774645-AF7021A7-38AE-457B-9351-8856432DF1AB Q26996829-D1C771CB-5B4E-4C94-B31B-9ECDF387E5F9 Q28068115-CAA7EE79-C4F5-4FA5-9430-845E8355E1C9 Q28082828-2AB12792-D6C1-41C2-8B73-92D6A93A3D80 Q28478285-BE171E6C-F13A-4FFD-AEAA-5BD98C3935CD Q28594186-79D6A722-247C-4145-96F1-2995326A8736 Q33713506-D116E331-F205-4D02-BE20-D1A9BED5A542 Q33933875-D00A28B4-E5D6-43F6-BE27-C519C41DC869 Q34129154-8093F4DD-1376-4256-B1BE-21D8C02F61C9 Q34442939-63095EA7-0210-4DA0-B527-A3A41B327C4D Q34524741-0E443AD0-A2DB-4917-A913-8ADA2AAE5377 Q34557233-F6A4158B-0C74-4386-80C9-0FE9D64A91C7 Q34988382-D3EC4F03-CBEB-4AC6-BE43-21CE6A578EC9 Q35077893-CE7DCD55-4B58-497C-A697-4D429DE21B0A Q35077925-0D433D6F-34A4-41A7-B30D-CD28B5DA0B04 Q35138135-FC77852D-7CB3-46E1-BE98-D0FA42E712FB Q35632645-172BF096-62FA-4CEC-A42A-DCCD4F997B77 Q35798978-9585CFBF-AA5D-4294-B65C-D6FF11DB0B0A Q35884077-C9042614-573B-4D3F-B7F3-4C46B4BB7044 Q36016491-4C63C4E2-F45E-4BD8-93FD-B0161CEDBE7E Q36328299-A27E8D9F-7CB4-4CFD-B7AC-840C6E05B713 Q36358324-D400E73C-0DDD-4F44-AE62-00069527F501 Q36606027-81314E46-3F75-48F3-B4BF-819F2534ECA2 Q37033307-D43BC6B0-F3B8-4FCC-AFB6-EE48CC5A7DA6 Q37046734-F89BD4B0-F16D-42A8-8206-9E72C8ABDEEB Q37170527-913E1448-0C40-4376-9A1E-9B3D7FBA47FD Q37196532-B843245E-21C9-4A48-BF87-027DE7CA837A Q37392837-F1825B5B-17D4-44A8-95C9-3C32AF147FC5 Q37397674-A77D2805-EC86-4058-9AAB-D591237157A3 Q37737545-A8F6D032-085B-4AF4-8C1B-5A278FB71144 Q38072479-8E844B7C-40D1-4A54-8427-4D51F0F3C483 Q38196803-FCDB3DDA-DEBD-4FFD-A38A-C811B76BB5A9 Q38207947-E9998FBA-3B7E-4810-AF03-9DF0B6B891F6 Q38569646-CD6797D3-1E85-4467-9CD5-03AD1132963F Q38575116-6E705909-0B65-400D-8E11-E7B2A65C5EF1 Q38714915-EBD5FE07-0FAA-4683-9458-BE0C175A573D Q39160967-A48B6E39-0E26-4F66-8FCC-9AB502B7027E

P2860

MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells

http://www.wikidata.org/entity/Q33638962

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

MUC16 provides immune protecti ...... een NK and ovarian tumor cells

@ast

MUC16 provides immune protecti ...... een NK and ovarian tumor cells

@en

type

label

MUC16 provides immune protecti ...... een NK and ovarian tumor cells

@ast

MUC16 provides immune protecti ...... een NK and ovarian tumor cells

@en

prefLabel

MUC16 provides immune protecti ...... een NK and ovarian tumor cells

@ast

MUC16 provides immune protecti ...... een NK and ovarian tumor cells

@en

P1433

Q33638962-1B303F57-C850-4A35-90A9-C3BF5366DFAC

P1476

Q33638962-7C1A2C79-85DB-4B17-A621-8791740E1D30

P2093

Q33638962-3AC1F837-7C2B-454B-A470-E2C53C1FFAC5

Q33638962-69E2D2DA-85A8-4E77-B1EB-B9582940B243

Q33638962-6F683EDA-9220-478F-8FB9-E9BD55077B6B

Q33638962-80C01E7E-DAB4-48A2-A88D-7C8E517F245E

Q33638962-8FC146AA-E98D-469E-A665-2221CF43FDC1

Q33638962-9CC6A071-73A1-4161-8266-87B21D40903F

Q33638962-A0A658D2-88A1-4894-B4C4-A11804728977

Q33638962-A470EE3E-A155-4170-8DE8-208A60A31F07

Q33638962-B9B15350-1012-4FE4-88B1-BD18DBF772F0

Q33638962-C464EC1C-92A3-4DA8-A69A-F303789207D8

P2860

Q33638962-013A6C90-842E-4C4A-9A1E-6C08DE14670B

Q33638962-03EDD17A-55FF-453A-AC9B-C8E4F0C2104A

Q33638962-0650CAA3-7E8E-423E-929E-BBF725B602DE

Q33638962-0F389D18-50B9-433C-B860-E62F437858A7

Q33638962-1DB88A2E-2E76-4E0A-AE55-E0A47DA0700D

Q33638962-230D8F75-D68F-479C-9B67-98D6B25FACD3

Q33638962-2ABAF5A7-66FF-4E91-9093-A3A7D5896DE6

Q33638962-2B1F984E-AA89-444B-A6AB-963049695476

Q33638962-2B463306-E57E-4FE1-88BA-08043D605126

Q33638962-30BF06E3-81E4-40FA-9AC3-DB933BE59524

P2888

Q33638962-4185C56F-B83B-4A7E-AE5B-E06451867334

P304

Q33638962-F5502CEB-6C08-4198-822B-7B519CDE1733

P31

Q33638962-90B8D819-4362-43F0-B04A-950701BB7A1E

P356

Q33638962-EBF4CC79-8D4A-444A-B5BB-EDCD44120C5F

P478

Q33638962-4A2CCE65-00FC-4700-92E2-F1C1A13CE0FD

P577

Q33638962-A6E6916C-DA36-41A9-8130-21DA7228CF80

P5875

Q33638962-BF00EC35-DA3C-4B96-9B4B-6F991792F8B6

P6179

Q33638962-23B546D4-0E8D-45BB-9DEA-B1B2C61A4069

P698

Q33638962-86E8AE74-0F3F-4695-BCC0-05F2F3FACDB4

P932

Q33638962-8328FF90-0852-4CA4-A0C4-FDE5BE8E84B3

P356

P1433

Molecular Cancer

P1476

MUC16 provides immune protecti ...... een NK and ovarian tumor cells

@en

P2093

Arvinder Kapur

http://www.w3.org/2001/XMLSchema#string

Claudine Rancourt

http://www.w3.org/2001/XMLSchema#string

Helen Holden

http://www.w3.org/2001/XMLSchema#string

Jennifer A A Gubbels

http://www.w3.org/2001/XMLSchema#string

Jennifer A Belisle

http://www.w3.org/2001/XMLSchema#string

Joseph P Connor

http://www.w3.org/2001/XMLSchema#string

Manish S Patankar

http://www.w3.org/2001/XMLSchema#string

Martine Migneault

http://www.w3.org/2001/XMLSchema#string

Mildred Felder

http://www.w3.org/2001/XMLSchema#string

Sachi Horibata

http://www.w3.org/2001/XMLSchema#string

P2860

HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer

The human natural killer cell immune synapse

Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors

Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125

Mucins in cancer: protection and control of the cell surface

Structure and function of the cell surface (tethered) mucins

Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells

HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C

Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells

P2888

P304

11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-4598-9-11

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41101567

http://www.w3.org/2001/XMLSchema#string

P6179

1045822292

http://www.w3.org/2001/XMLSchema#string

P698

20089172

http://www.w3.org/2001/XMLSchema#string

P932

2818693

http://www.w3.org/2001/XMLSchema#string